Sarepta Therapeutics Inc (SRPT)

Quick ratio

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Cash US$ in thousands 427,300 428,430 541,932 851,929 871,668 966,777 1,038,620 868,565 1,233,880 2,115,870 1,599,110 1,697,280 1,481,840 1,502,650 1,474,640 1,639,960 1,764,210 835,080 724,829 808,591
Short-term investments US$ in thousands 963,500 1,247,820 1,191,610 1,008,790 1,010,430 1,022,600 1,033,900 1,059,450 779,548 0 0 30,000 255,997 435,923 341,467 421,349 406,940 289,668 324,063 294,478
Receivables US$ in thousands 378,806 403,058 318,855 236,808 223,836 217,939 201,509 203,854 178,194 152,990 149,787 127,520 118,203 101,340 121,827 104,028 106,875 90,879 68,032 56,981
Total current liabilities US$ in thousands 608,709 653,659 450,743 498,654 536,884 619,604 602,916 545,566 454,962 452,733 373,443 425,022 364,736 416,026 378,388 354,896 306,429 264,767 215,856 162,089
Quick ratio 2.91 3.18 4.55 4.21 3.92 3.56 3.77 3.91 4.82 5.01 4.68 4.36 5.09 4.90 5.12 6.10 7.43 4.59 5.17 7.16

March 31, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($427,300K + $963,500K + $378,806K) ÷ $608,709K
= 2.91

The quick ratio of Sarepta Therapeutics Inc has shown a fluctuating trend over the past few quarters. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets.

The quick ratio has generally been above 1, indicating that the company has enough liquid assets to cover its current liabilities. A quick ratio above 1 is considered healthy as it suggests a company is able to pay off its short-term obligations without relying heavily on inventory sales.

Looking at the trend, the quick ratio has been above 3 in most quarters, indicating a strong liquidity position. The highest quick ratio was observed in March 2020 at 7.43, signaling a robust ability to cover short-term liabilities with liquid assets.

However, the quick ratio has shown some fluctuations over the quarters, which could be due to changes in the company's current assets and liabilities composition. Investors and analysts typically prefer a stable and consistent quick ratio over time, although variations can be expected depending on the company's business cycle and operating environment.

Overall, Sarepta Therapeutics Inc's quick ratio indicates a healthy liquidity position, which is important for ensuring the company's short-term financial stability.